References

Bickford, L. R., G. Agollah, R. Drezek, and T. K. Yu. 2010. Silica-gold nanoshells as potential intraoperative molecular probes for HER2-overexpression in ex vivo breast tissue using near-infrared reflectance confocal microscopy. Breast Cancer Research and Treatment 120(3):547–555.

Boisselier, E., and D. Astruc. 2009. Gold nanoparticles in nanomedicine: Preparations, imaging, diagnostics, therapies and toxicity. Chemical Society Reviews 38(6):1759–1782.

Davis, M. E., J. E. Zuckerman, C. H. Choi, D. Seligson, A. Tolcher, C. A. Alabi, Y. Yen, J. D. Heidel, and A. Ribas. 2010. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464(7291):1067–1070.

Debbage, P. 2009. Targeted drugs and nanomedicine: Present and future. Current Pharmaceutical Design 15(2):153–172.

Fan, R., O. Vermesh, A. Srivastava, B. K. H. Yen, L. Qin, N. Ahmad, G. A. Kwong, C. Liu, J. Gould, L. Hood, and J. R. Heath. 2008. Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood. Nature Biotechnology 26(12):1373–1378.

FDA (Food and Drug Administration). 2009. FDA regulation of nanotechnology products. http://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/NanotechnologyTaskForce/ucm115441.htm (accessed April 29, 2011).

Fischer, H. C., and W. C. W. Chan. 2007. Nanotoxicity: The growing need for in vivo study. Current Opinion in Biotechnology 18(6):565–571.

Gao, J. H., H. W. Gu, and B. Xu. 2009. Multifunctional magnetic nanoparticles: Design, synthesis and biomedical applications. Accounts of Chemical Research 42(8):1097–1107.

Heath, J. R., M. E. Davis, and L. Hood. 2009. Nanomedicine targets cancer. Scientific American 300(2):44–51.

IOM (Institute of Medicine). 2010. Evaluation of biomarkers and surrogate endpoints in chronic disease. Washington, DC: The National Academies Press.

Keiner, S. 2008. Room at the bottom? Potential state and local strategies for managing the risks and benefits of nanotechnology. http://www.nanotechproject.org/process/assets/files/6112/pen11_keiner.pdf (accessed April 29, 2011).



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 69
References Bickford, L. R., G. Agollah, R. Drezek, and T. K. Yu. 2010. Silica-gold nanoshells as potential intraoperative molecular probes for HER2-overexpression in ex vivo breast tissue us- ing near-infrared reflectance confocal microscopy. Breast Cancer Research and Treatment 120(3):547–555. Boisselier, E., and D. Astruc. 2009. Gold nanoparticles in nanomedicine: Preparations, imag- ing, diagnostics, therapies and toxicity. Chemical Society Reviews 38(6):1759–1782. Davis, M. E., J. E. Zuckerman, C. H. Choi, D. Seligson, A. Tolcher, C. A. Alabi, Y. Yen, J. D. Heidel, and A. Ribas. 2010. Evidence of RNAi in humans from systemically adminis- tered siRNA via targeted nanoparticles. Nature 464(7291):1067–1070. Debbage, P. 2009. Targeted drugs and nanomedicine: Present and future. Current Pharma- ceutical Design 15(2):153–172. Fan, R., O. Vermesh, A. Srivastava, B. K. H. Yen, L. Qin, N. Ahmad, G. A. Kwong, C. Liu, J. Gould, L. Hood, and J. R. Heath. 2008. Integrated barcode chips for rapid, mul- tiplexed analysis of proteins in microliter quantities of blood. Nature Biotechnology 26(12):1373–1378. FDA (Food and Drug Administration). 2009. FDA regulation of nanotechnology products. http://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/Nano technologyTaskForce/ucm115441.htm (accessed April 29, 2011). Fischer, H. C., and W. C. W. Chan. 2007. Nanotoxicity: The growing need for in vivo study. Current Opinion in Biotechnology 18(6):565–571. Gao, J. H., H. W. Gu, and B. Xu. 2009. Multifunctional magnetic nanoparticles: Design, synthesis and biomedical applications. Accounts of Chemical Research 42(8):1097–1107. Heath, J. R., M. E. Davis, and L. Hood. 2009. Nanomedicine targets cancer. Scientific American 300(2):44–51. IOM (Institute of Medicine). 2010. Evaluation of biomarkers and surrogate endpoints in chronic disease. Washington, DC: The National Academies Press. Keiner, S. 2008. Room at the bottom? Potential state and local strategies for managing the risks and benefits of nanotechnology. http://www.nanotechproject.org/process/assets/files/6112/ pen11_keiner.pdf (accessed April 29, 2011). 69

OCR for page 69
70 NANOTECHNOLOGY AND ONCOLOGY Kostarelos, K., A. Bianco, and M. Prato. 2009. Promises, facts and challenges for carbon nanotubes in imaging and therapeutics. Nature Nanotechnology 4(10):627–633. Lammers, T., W. E. Hennink, and G. Storm. 2008. Tumour-targeted nanomedicines: Prin- ciples and practice. British Journal of Cancer 99(3):392–397. Li, K. 2010. Biologic barriers to in vivo nanomedicine delivery: Major hurdles for clinical transla- tion. Paper presented at the NCPF workshop on Policy Issues in Nanotechnology and Oncology, Washington, DC. McLaren, C. E., S. Fujikawa-Brooks, W. P. Chen, D. L. Gillen, D. Pelot, E. W. Gerner, and F. L. Meyskens Jr. 2008. Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas. Cancer Prevention Research 1(7):514–521. Meyskens, J., F. L., C. E. McLaren, D. Pelot, S. Fujikawa-Brooks, P. M. Carpenter, E. Hawk, G. Kelloff, M. J. Lawson, J. Kidao, J. McCracken, C. G. Albers, D. J. Ahnen, D. K. Turgeon, S. Goldschmid, P. Lance, C. H. Hagedorn, D. L. Gillen, and E. W. Gerner. 2008. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled, double-blind trial. Cancer Prevention Re- search 1(1):32–38. Moghimi, S. M., A. C. Hunter, and J. C. Murray. 2005. Nanomedicine: Current status and future prospects. FASEB Journal 19(3):311–330. NCI (National Cancer Institute). 2010a. NCI Alliance for Nanotechnology in Cancer. http:// nano.cancer.gov/ (accessed November 17, 2010). NCI. 2010b. Understanding nanotechnology. http://nano.cancer.gov/learn/understanding/ (accessed January 20, 2011). Nie, S. M., Y. Xing, G. J. Kim, and J. W. Simons. 2007. Nanotechnology applications in cancer. Annual Review of Biomedical Engineering 9:257–288. NNI (National Nanotechnology Initiative). 2010. What is nanotechnology? http://www.nano .gov/html/facts/whatIsNano.html (accessed January 3, 2011). Peer, D., J. M. Karp, S. Hong, O. C. FaroKhzad, R. Margalit, and R. Langer. 2007. Nanocar- riers as an emerging platform for cancer therapy. Nature Nanotechnology 2(12):751–760. Riehemann, K., S. W. Schneider, T. A. Luger, B. Godin, M. Ferrari, and H. Fuchs. 2009. Nanomedicine—Challenge and perspectives. Angewandte Chemie International Edition in English 48(5):872–897. Sakamoto, J. H., A. L. van de Ven, B. Godin, E. Blanco, R. E. Serda, A. Grattoni, A. Ziemys, A. Bouamrani, T. Hu, S. I. Ranganathan, E. De Rosa, J. O. Martinez, C. A. Smid, R. M. Buchanan, S. Y. Lee, S. Srinivasan, M. Landry, A. Meyn, E. Tasciotti, X. Liu, P. Decuzzi, and M. Ferrari. 2010. Enabling individualized therapy through nanotechnology. Phar- macology Research 62(2):57–89. Schierow, L.-J. 2008. Engineered nanoscale materials and derivative products: Regulatory chal- lenges, Order Code RL34332 Congressional Research Service. Siddiqui, I. A., V. M. Adhami, D. J. Bharali, B. B. Hafeez, M. Asim, S. I. Khwaja, N. Ahmad, H. Cui, S. A. Mousa, and H. Mukhtar. 2009. Introducing nanochemoprevention as a novel approach for cancer control: Proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Research 69(5):1712–1716. Siegrist, M., M. E. Cousin, H. Kastenholz, and A. Wiek. 2007. Public acceptance of nan- otechnology foods and food packaging: The influence of affect and trust. Appetite 49(2):459–466. Song, Y., X. Li, and X. Du. 2009. Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma. European Respiratory Journal 34(3):559–567. Suresh, S. 2007. Biomechanics and biophysics of cancer cells. Acta Biomateriala 3(4):413–438. Trehin, R., J. L. Figueiredo, M. J. Pittet, R. Weissleder, L. Josephson, and U. Mahmood. 2006. Fluorescent nanoparticle uptake for brain tumor visualization. Neoplasia 8(4):302–311.

OCR for page 69
71 REFERENCES Wang, J., S. Tian, R. A. Petros, M. E. Napier, and J. M. DeSimone. 2010. The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies. Journal of the American Chemical Society 132(32):11306–11313. Zhao, Y., and H. Singh Nalwa. 2006. Nanotoxicology: Interactions of nanomaterials with biological systems. Los Angeles, CA: American Scientific Publishers.

OCR for page 69